company-logoAdial Pharmaceuticals, Inc.$0.36
%
Analyst Rating: Hold

Stock Details

CEO

Cary John Claiborne MBA

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

5

Address

1180 Seminole Trail, Charlottesville, VA, 22901

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Top Competitors

Income Statement  

Financials

Selected Year

Revenue Estimates

EPS Estimates

Net Income Estimates

Price target for Adial Pharmaceuticals, Inc.  $0.36

$0

Min Forecast(+0% )

$249.61

Avg Forecast( +0% )

$325

Max Forecast(+0%)

EPS

Revenue

Institutional Holder

Loading institutional holder data...

Congress Tracker 

    Showing 0 of 0 results

    Insider Trading of Key Employees

      Showing 0 of 0 results

      Financial News: ADIL